| __timestamp | Halozyme Therapeutics, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 305409000 |
| Thursday, January 1, 2015 | 40028000 | 377080000 |
| Friday, January 1, 2016 | 45853000 | 432829000 |
| Sunday, January 1, 2017 | 53816000 | 496079000 |
| Monday, January 1, 2018 | 60804000 | 557616000 |
| Tuesday, January 1, 2019 | 77252000 | 658498000 |
| Wednesday, January 1, 2020 | 45736000 | 770456000 |
| Friday, January 1, 2021 | 50323000 | 840100000 |
| Saturday, January 1, 2022 | 143526000 | 944700000 |
| Sunday, January 1, 2023 | 149182000 | 1136600000 |
| Monday, January 1, 2024 | 154335000 | 1464300000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and growth. Over the past decade, Vertex Pharmaceuticals Incorporated and Halozyme Therapeutics, Inc. have demonstrated contrasting strategies in this area. From 2014 to 2023, Vertex's SG&A expenses surged by approximately 270%, reflecting its aggressive expansion and investment in administrative capabilities. In contrast, Halozyme's expenses grew by about 315%, indicating a significant ramp-up in its operational activities.
Vertex consistently outpaced Halozyme in absolute SG&A spending, with 2023 figures showing Vertex's expenses at nearly eight times those of Halozyme. This disparity highlights Vertex's larger scale and broader market reach. However, Halozyme's rapid increase in SG&A expenses suggests a strategic shift towards scaling operations and enhancing market presence. As these companies continue to evolve, their SG&A strategies will be pivotal in shaping their competitive positions in the biotech industry.
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.